NEW YORK, NY, June 2, 2023 — Lupus Research Alliance clinical research affiliate Lupus Therapeutics will collaborate with Novartis Pharmaceuticals Corporation to conduct three Phase 3 clinical trials testing an investigational therapeutic ianalumab for systemic lupus erythematosus and lupus nephritis through the Lupus Clinical Investigators Network (LuCIN) at top academic centers throughout North America.
The full press release is available on the Lupus Therapeutics website.
Tags: ianalumab, lupus therapeutics, Lucin, Lupus Clinical Investigators Network, Novartis Pharmaceuticals